Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7

• Published in: Leukemia Vol. 13; no. 3; pp. 376 - 385
• Main Authors: HASLE, H, ARICO, M, KARDOS, G, KERNDRUP, G, MANN, G, NIEMEYER, C, PTOSZKOVA, H, RITTER, J, SLATER, R, STARY, J, STOLLMANN-GIBBELS, B, TESTI, A, BASSO, G, VAN WERING, E, ZIMMERMANN, M, BIONDI, A, RAJNOLDI, A. C, CREUTZIG, U, FENU, S, FONATSCH, C, HAAS, O, HARBOTT, J
• Format: Journal Article
• Language: English
• Published: London Nature Publishing 01.03.1999; Nature Publishing Group
• Subjects: Abnormalities; Acute myeloid leukemia; Anemia; Biological and medical sciences; Blast cells; Bone marrow; Bone marrow transplantation; Chemotherapy; Children; Chromosome 7; Chromosome deletion; Chromosomes; Cytogenetics; Diagnosis; Hematologic and hematopoietic diseases; Juveniles; Leukemia; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Monosomy; Myelodysplastic syndrome; Myelodysplastic syndromes; Myelomonocytic leukemia; Patients; Refractory anemia; Survival; Transplantation; Human; Chromosomal aberration; Myelomonocytic leukemia; Prognosis; Family study; Acute; Aneuploidy; Malignant hemopathy; Chromosome C7; Genetic determinism; Treatment; Cytogenetics; Genetics; Child; Karyotype; Monosomy; Acute myelocytic leukemia
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/sj.leu.2401342

We reviewed the clinical features, treatment, and outcome of 100 children with myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia (JMML), and acute myeloid leukemia (AML) associated with complete monosomy 7 (−7) or deletion of the long arm of chromosome 7 (7q−). Patients with therapy-induced disease were excluded. The morphologic diagnoses according to modified FAB criteria were: MDS in 72 (refractory anemia (RA) in 11, RA with excess of blasts (RAEB) in eight, RAEB in transformation (RAEB-T) in 10, JMML in 43), and AML in 28. The median age at presentation was 2.8 years (range 2 months to 15 years), being lowest in JMML (1.1 year). Loss of chromosome 7 as the sole cytogenetic abnormality was observed in 75% of those with MDS compared with 32% of those with AML. Predisposing conditions (including familial MDS/AML) were found in 20%. Three-year survival was 82% in RA, 63% in RAEB, 45% in JMML, 34% in AML, and 8% in RAEB-T. Children with −7 alone had a superior survival than those with other cytogenetic abnormalities: this was solely due to a better survival in MDS (3-year survival 56 vs 24%). The reverse was found in AML (3-year survival 13% in −7 alone vs 44% in other cytogenetic groups). Stable disease for several years was documented in more than half the patients with RA or RAEB. Patients with RA, RAEB or JMML treated with bone marrow transplantation (BMT) without prior chemotherapy had a 3-year survival of 73%. The morphologic diagnosis was the strongest prognostic factor. Only patients with a diagnosis of JMML fitted what has previously been referred to as the monosomy 7 syndrome. Our data give no support to the concept of monosomy 7 as a distinct syndrome.